RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
-7.28%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$2.1B
AUM Growth
+$2.1B
(-19%)
Cap. Flow
-$445M
Cap. Flow
% of AUM
-21.18%
Top 10 Holdings %
Top 10 Hldgs %
55.38%
Holding
76
New
4
Increased
13
Reduced
27
Closed
8
Top Buys
| 1 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$41.2M |
| 2 |
Boston Scientific
BSX
|
$20.2M |
| 3 |
Biohaven
BHVN
|
$13.5M |
| 4 |
Regenxbio
RGNX
|
$9.01M |
| 5 |
Evolent Health
EVH
|
$6.86M |
Top Sells
| 1 |
MDVL
MedAvail Holdings, Inc. Common Stock
MDVL
|
$206M |
| 2 |
Krystal Biotech
KRYS
|
$65.3M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$42.4M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$42.4M |
| 5 |
Amicus Therapeutics
FOLD
|
$31.9M |
Sector Composition
| 1 | Healthcare | 96.1% |
| 2 | Industrials | 3.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
1
DELISTED
Immunogen Inc
IMGN
| $278M | 13.22% | 17,503,417 -227,000 | -1% | -$3.6M |
|
|
2
Krystal Biotech
KRYS
$4.27B
| $232M | 11.06% | 2,003,367 -563,294 | -22% | -$65.3M |
|
|
3
Amicus Therapeutics
FOLD
$2.34B
| $206M | 9.8% | 16,944,621 -2,622,340 | -13% | -$31.9M |
|
4
Akero Therapeutics
AKRO
$3.74B
| $89.5M | 4.26% | 1,769,684 -41,988 | -2% | -$2.12M |
|
|
AUGX
5
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $80.5M | 3.83% | 15,630,327 | – | – |
|
6
Replimune Group
REPL
$422M
| $71.2M | 3.39% | 4,163,922 -256,611 | -6% | -$4.39M |
|
7
LivaNova
LIVN
$3.08B
| $58.2M | 2.77% | 1,100,492 | – | – |
|
|
DCPH
8
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $56.9M | 2.71% | 4,475,384 -403,182 | -8% | -$5.13M |
|
9
Pliant Therapeutics
PLRX
$101M
| $46.4M | 2.21% | 2,678,099 | – | – |
|
10
Celldex Therapeutics
CLDX
$1.47B
| $45M | 2.14% | 1,635,938 -60,066 | -4% | -$1.65M |
|
|
11
Regenxbio
RGNX
$451M
| $42.4M | 2.02% | 2,574,042 +547,466 | +27% | +$9.01M |
|
12
Immunovant
IMVT
$2.56B
| $42.3M | 2.01% | 1,102,514 -818,638 | -43% | -$31.4M |
|
|
RYZB
13
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $41.2M | 1.96% | +1,857,706 | New | +$41.2M |
|
|
14
Boston Scientific
BSX
$156B
| $40.9M | 1.94% | 774,200 +383,022 | +98% | +$20.2M |
|
|
CTLT
15
DELISTED
CATALENT, INC.
CTLT
| $39.8M | 1.89% | 873,966 -288,200 | -25% | -$13.1M |
|
16
Penumbra
PEN
$10.6B
| $37.5M | 1.78% | 155,076 +16,106 | +12% | +$3.9M |
|
17
Elevance Health
ELV
$71.8B
| $37.2M | 1.77% | 85,378 +7,065 | +9% | +$3.08M |
|
18
Zymeworks
ZYME
$1.12B
| $35.9M | 1.71% | 5,661,230 | – | – |
|
19
Beam Therapeutics
BEAM
$1.66B
| $35.3M | 1.68% | 1,469,725 -15,474 | -1% | -$372K |
|
20
Scholar Rock
SRRK
$3.14B
| $33.6M | 1.6% | 4,733,248 +329,408 | +7% | +$2.34M |
|
21
Ventyx Biosciences
VTYX
$171M
| $32.3M | 1.54% | 929,900 -10,593 | -1% | -$368K |
|
22
Humana
HUM
$36.5B
| $29.1M | 1.39% | 59,851 +13,541 | +29% | +$6.59M |
|
23
Repare Therapeutics
RPTX
$71.7M
| $29M | 1.38% | 2,404,695 -23,640 | -1% | -$286K |
|
24
Fate Therapeutics
FATE
$120M
| $27.8M | 1.32% | 13,124,427 | – | – |
|
25
Cabaletta Bio
CABA
$133M
| $27M | 1.28% | 1,774,252 +403,953 | +29% | +$6.15M |
|